[Epidemiology of the meningococcal disease in Catalonia before and after vaccination against serogroup C]
- PMID: 20111820
- DOI: 10.1590/s1135-57272009000500013
[Epidemiology of the meningococcal disease in Catalonia before and after vaccination against serogroup C]
Abstract
Backgrounds: Meningococcal disease remains a serious public health problem worldwide. In Catalonia, after implementing the vaccination program, there has been a significant decrease in cases caused by meningococcus C.
Methods: Reported cases of meningococcal disease between 1997 and 2008 were analyzed to determine the evolution after the introduction of a conjugated vaccine in Catalonia.
Results: In < 6 years, the incidence rate of serogroup C fell from 7.6 to 0.6 per 100,000 persons/year in the periods before (1997-2000) and after (2001-2007) the introduction of the conjugate vaccine. In serogroup B, the reduction was from 15.4 to 11.1. In < 20 years case-fatality-rate increased only in serogroup B (3% and 7.4%). Serosubtype P1.15was the most frequent in serogroup B (31%), mainly associated with serotype 4 (80%), and in serogroup C subtype P1.5 (36%), with serotype 2a (86%). During 2008, 5 apparently unrelated cases of B:2a:P1.5 were identified in the same geographic area, with a case-fatality-rate of 80%.
Conclusions: Exhaustive surveillance of circulating meningococcal strains is essential.
Similar articles
-
Changes in the evolution of meningococcal disease, 2001-2008, Catalonia (Spain).Vaccine. 2009 May 26;27(25-26):3496-8. doi: 10.1016/j.vaccine.2009.01.045. Epub 2009 Feb 5. Vaccine. 2009. PMID: 19200816
-
Changes in Meningococcal Strains in the Era of a Serogroup C Vaccination Campaign: Trends and Evolution in Belgium during the Period 1997-2012.PLoS One. 2015 Oct 1;10(10):e0139615. doi: 10.1371/journal.pone.0139615. eCollection 2015. PLoS One. 2015. PMID: 26425857 Free PMC article.
-
Epidemiology of serogroup C and Y invasive meningococcal disease (IMD) in Ontario, 2000-2013: Vaccine program impact assessment.Vaccine. 2015 Oct 13;33(42):5678-5683. doi: 10.1016/j.vaccine.2015.08.023. Epub 2015 Aug 20. Vaccine. 2015. PMID: 26299749
-
Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy.Expert Rev Vaccines. 2009 May;8(5):529-42. doi: 10.1586/erv.09.18. Expert Rev Vaccines. 2009. PMID: 19397410 Review.
-
New frontiers in meningococcal vaccines.Expert Rev Vaccines. 2011 May;10(5):617-34. doi: 10.1586/erv.11.50. Expert Rev Vaccines. 2011. PMID: 21604983 Review.
Cited by
-
Invasive Meningococcal Disease: What We Should Know, Before It Comes Back.Open Forum Infect Dis. 2019 Feb 7;6(3):ofz059. doi: 10.1093/ofid/ofz059. eCollection 2019 Mar. Open Forum Infect Dis. 2019. PMID: 30949522 Free PMC article.
-
Meningococcal disease serogroup C.Risk Manag Healthc Policy. 2012;5:1-15. doi: 10.2147/RMHP.S12711. Epub 2012 Mar 8. Risk Manag Healthc Policy. 2012. PMID: 22427737 Free PMC article.
-
Epidemiology of vaccine-preventable invasive diseases in Catalonia in the era of conjugate vaccines.Hum Vaccin Immunother. 2013 Mar;9(3):681-91. doi: 10.4161/hv.23266. Epub 2013 Jan 9. Hum Vaccin Immunother. 2013. PMID: 23303166 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical